In Brief: DuPont Merck's ReVia
Executive Summary
DuPont Merck's ReVia: Prescription threshold for postmarketing studies of naltrexone has not yet been reached, firm says March 12. DuPont Merck is committed to Phase IV studies of the alcoholism treatment if annual scripts top 200,000 per year. An NDA study was published in the March issue of the American Medical Association's Archives of General Psychiatry...